Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis

BACKGROUND: Neoadjuvant anthracycline-taxane-based chemotherapy (ChT) is a standard of care treatment option for stage II–III breast cancer (BC) patients. However, the optimal duration of neoadjuvant ChT has been poorly investigated so far. MATERIAL AND METHODS: We retrospectively retrieved clinical...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ther Adv Med Oncol
Autori principali: Lobefaro, Riccardo, Zattarin, Emma, Nichetti, Federico, Prisciandaro, Michele, Ligorio, Francesca, Brambilla, Marta, Sepe, Pierangela, Corti, Francesca, Peverelli, Giorgia, Ottini, Arianna, Beninato, Teresa, Mazzeo, Laura, Rea, Carmen G., Mariani, Gabriella, de Braud, Filippo, Bianchi, Giulia V., Vernieri, Claudio, Capri, Giuseppe
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724266/
https://ncbi.nlm.nih.gov/pubmed/33335565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920970081
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi